Literature DB >> 16512832

Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia.

Valery Leytin1, Sergiy Mykhaylov, Alison F Starkey, David J Allen, Herbert Lau, Heyu Ni, John W Semple, Alan H Lazarus, John Freedman.   

Abstract

We have previously shown that injection of anti-glycoprotein (GP) IIb induces murine immune thrombocytopenia (ITP) and that intravenous immunoglobulin (IVIg) ameliorates ITP. We hypothesise that murine ITP may be associated with platelet apoptosis, which is upregulated by anti-GPIIb and downregulated by IVIg. The current study demonstrated that anti-GPIIb injection induced three critical apoptosis manifestations in platelets: (i) mitochondrial inner transmembrane potential (delta psi m) depolarisation; (ii) caspase-3 activation; and (iii) phosphatidylserine (PS) exposure. IVIg administration inhibited caspase-3 activation and PS exposure, but not delta psi m-depolarisation, in anti-GPIIb-treated platelets, demonstrating that IVIg ameliorates thrombocytopenia concomitantly with inhibiting late, but not early mechanisms of platelet apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16512832     DOI: 10.1111/j.1365-2141.2006.05981.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

Review 2.  Markers of platelet apoptosis: methodology and applications.

Authors:  Armen V Gyulkhandanyan; Asuman Mutlu; John Freedman; Valery Leytin
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

3.  The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187.

Authors:  Valery Leytin; Asuman Mutlu; Sergiy Mykhaylov; David J Allen; Armen V Gyulkhandanyan; John Freedman
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 4.  Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.

Authors:  Jose Ramon Gonzalez-Porras; Jose Maria Bastida
Journal:  Ther Adv Drug Saf       Date:  2018-04-19

Review 5.  Clinical updates in adult immune thrombocytopenia.

Authors:  Michele P Lambert; Terry B Gernsheimer
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

6.  A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil.

Authors:  Paula Yurie Tanaka; Luis Fernando Pracchia; Marcelo Bellesso; Dalton Alencar Fischer Chamone; Edenilson Eduardo Calore; Juliana Pereira
Journal:  Ann Hematol       Date:  2009-06-04       Impact factor: 3.673

7.  Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course.

Authors:  Sarina Levy-Mendelovich; Shraga Aviner; Nechama Sharon; Hagit Miskin; Joanne Yacobovich; Gili Kenet; Hagit Hauschner; Nurit Rosenberg
Journal:  Pediatr Res       Date:  2021-01-27       Impact factor: 3.756

8.  Investigating caspases and other markers of apoptosis in ITP.

Authors:  Oliver Speer; Markus Schmugge
Journal:  Ann Hematol       Date:  2010-04-22       Impact factor: 3.673

9.  Platelet Apoptosis in Adult Immune Thrombocytopenia: Insights into the Mechanism of Damage Triggered by Auto-Antibodies.

Authors:  Nora P Goette; Ana C Glembotsky; Paola R Lev; Matías Grodzielski; Geraldine Contrufo; Marta S Pierdominici; Yesica R Espasandin; Dardo Riveros; Alejandro J García; Felisa C Molinas; Paula G Heller; Rosana F Marta
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

10.  Platelet volume and plateletcrit in dogs with presumed primary immune-mediated thrombocytopenia.

Authors:  D Schwartz; L Sharkey; P J Armstrong; C Knudson; J Kelley
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.